Serina Therapeutics (SER) Liabilities and Shareholders Equity (2017 - 2026)

Serina Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $7.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 3.38% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.0 million (down 1.92% YoY) and the FY2025 annual result came in at $7.0 million, up 3.38% from the prior year.
• Liabilities and Shareholders Equity retreated to $7.0 million in Q4 2025 per SER's latest filing, from $12.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $12.4 million in Q3 2025 and troughed at $497000.0 in Q1 2023.
• A 5-year average of $5.7 million and a median of $5.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 81.7% in 2023, then surged 2084.31% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.2 million in 2021, then increased by 2.76% to $3.2 million in 2022, then jumped by 176.7% to $9.0 million in 2023, then slipped by 25.02% to $6.7 million in 2024, then increased by 3.38% to $7.0 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.0 million, $12.4 million, and $8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.